View Older Stories View More Recent Stories

Oct 22, 2015 08:05AM Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
Oct 14, 2015 07:05AM Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
Oct 10, 2015 08:00AM Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
Oct 5, 2015 07:00AM Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B –
Sep 19, 2015 02:00PM Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
Sep 19, 2015 02:00PM Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
Sep 18, 2015 03:00PM Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
Sep 18, 2015 03:00PM Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
Sep 17, 2015 07:00AM Matinas BioPharma Appoints International Expert and Thought Leader on Invasive Fungal Infections Peter G. Pappas, M.D., FACP, to Scientific Advisory Board
Sep 2, 2015 07:05AM Matinas BioPharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015
Sep 2, 2015 07:05AM Matinas BioPharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015
Sep 1, 2015 07:00AM Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Sep 1, 2015 07:00AM Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Aug 18, 2015 07:00AM Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA
Jul 27, 2015 07:05AM Matinas BioPharma Announces Abstract on Pharmacokinetics and Efficacy of Encochleated Atovaquone in Murine Model of Pneumocystis Accepted for Oral Presentation at IDWeek 2015
Jul 27, 2015 07:05AM Matinas BioPharma Announces Abstract on Pharmacokinetics and Efficacy of Encochleated Atovaquone in Murine Model of Pneumocystis Accepted for Oral Presentation at IDWeek 2015
Jul 23, 2015 07:05AM Matinas BioPharma Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
Jul 23, 2015 07:05AM Matinas BioPharma Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
Jul 14, 2015 07:35AM Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015
Jul 14, 2015 07:35AM Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015
Jul 7, 2015 07:35AM Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
Jul 7, 2015 07:35AM Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
Jun 15, 2015 07:05AM Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
Jun 15, 2015 07:05AM Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
Jun 10, 2015 07:35AM Matinas BioPharma to Present at the BIO International Convention on June 18, 2015
Jun 4, 2015 07:05AM Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
Jun 4, 2015 07:05AM Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
Jun 1, 2015 08:00AM Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
May 28, 2015 07:05AM Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
May 28, 2015 07:05AM Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
May 26, 2015 07:35AM Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
Apr 10, 2015 12:20PM Matinas BioPharma Completes Private Placement of $10 Million
Apr 10, 2015 12:20PM Matinas BioPharma Completes Private Placement of $10 Million
Apr 7, 2015 08:05AM Matinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015
Apr 7, 2015 08:05AM Matinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015
Mar 30, 2015 08:05AM Matinas BioPharma Completes Enrollment in First Human Trial of MAT9001
Mar 30, 2015 08:05AM Matinas BioPharma Completes Enrollment in First Human Trial of MAT9001
Mar 4, 2015 08:05AM Matinas BioPharma to Present at the 27th Annual ROTH Conference on March 11, 2015
Feb 5, 2015 08:05AM Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Jan 30, 2015 08:25AM Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
Jan 7, 2015 07:35AM Matinas BioPharma to Present at the Biotech Showcase 2015 Conference on January 14, 2015
Dec 23, 2014 08:05AM Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
Nov 24, 2014 07:05AM Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
Nov 12, 2014 07:35AM Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
Nov 10, 2014 07:35AM Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
Nov 4, 2014 07:35AM Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
Oct 29, 2014 07:35AM Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
Oct 20, 2014 08:05AM Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
Sep 30, 2014 07:35AM Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
Jul 31, 2014 08:05AM Matinas BioPharma Launches Digital Corporate Communication Channels
View More Recent Stories View Older Stories